Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Company on $10 million Secondary Public Offering of Cyclacel Pharmaceuticals, Inc.
NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Laidlaw & Company (UK) Ltd. as sole underwriter in a $10 million secondary public offering for Cyclacel Pharmaceuticals, Inc. (“CYCC.” NASDAQ). The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of 2,857,143 shares of common stock at an offering price of $3.50 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Richard Friedman and Stephen Cohen.
- SEC Extends Filing Deadlines for Public Companies and Registered Investment Advisers Affected by COVID-19 - April 1, 2020
- Business Interruption Insurance - April 1, 2020
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.7 Million Overnight Bought Offering of Cel-Sci Common Stock - March 26, 2020